Why are so few randomized trials useful, and what can we do about it?
Merrick Zwarenstein, Andy Oxman
págs. 1125-1126
Edgardo Abalos, Craig Ramsay, Kirsty McCormack, Shaun Treweek, Merrick Zwarenstein, Marion Campbell
págs. 1127-1133
David Moher, Joanne Barnes, Heather Boon, Paula A. Rochon, Claire Bombardier, Joel J. Gagnier
págs. 1134-1149
págs. 1150-1154
Recurrent events counted in evaluations of predictive accuracy
Richard H. Osborne, Kim L. Bennell, Terry P. Haines, Keith D. Hill
págs. 1155-1161
Empirical-Bayes adjustment improved conventional estimates in postmarketing drug-safety studies
Vincenzo Bagnardi, Edoardo Botteri, Giovanni Corrao
págs. 1162-1168
Peter R. Croft, Kelvin Jordan, Umesh T. Kadam
págs. 1169-1173
Mary D. Slavin, Ronald K. Hambleton, Pengsheng Ni, Stephen M. Haley, Alan M. Jette
págs. 1174-1182
Longer response scales improved the acceptability and performance of the Nottingham Health Profile
Véronique Kolly, Agatta Cleopas, Thomas V. Perneger
págs. 1183-1190
Catherine L. Saunders, Martin C. Gulliford
págs. 1191-1198
Martin Eccles, Carl May, James Mason, Tiago Moreira
págs. 1199-1206
Maroeska M. Rovers, Anne G.M. Schilder, Cornelis K. van der Ent, Walter A.F. Balemans, Elisabeth A.M. Sanders, Gerhard A. Zielhuis
págs. 1207-1212
Health problems were the strongest predictors of attrition during follow-up of the GAZEL cohort
Annette Leclerc, Isabelle Niedhammer, Marcel Goldberg, Jean François Chastang, Marie Zins
págs. 1213-1221
A low tension between individual and societal time aspects in health improved outcomes
James F. Fries, Monica Ortendahl
págs. 1222-1227
Response to Carter et al.: a survey identified publication bias in the secondary literature
R. Brian Haynes, Nancy Wilczynski, Michal Bohdanowicz
pág. 1228
© 2001-2024 Fundación Dialnet · Todos los derechos reservados